Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Natural, innate improvements in multiple sclerosis disability.
Abnormal Baseline Brain Activity in Patients with Multiple Sclerosis With Simple Spinal Cord Involvement Detected by Resting-State Functional Magnetic Resonance Imaging.
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.
The Alice in Wonderland syndrome: an unusual in acute disseminated encephalomyelitis.
Placebo Cohorts in Phase-3 MS Treatment Trials - Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data.
Are there Epstein-Barr virus seronegative patients with multiple sclerosis?
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Immunomodulators for multiple sclerosis may ameliorate spinal bone loss.
Patients' experiences of adapting to multiple sclerosis: a qualitative study.
Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Biologic therapies: lessons from multiple sclerosis.
Smoking and Risk of Multiple Sclerosis: Evidence of Modification by NAT1 Variants.
The role of microglial activation in disease progression.
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Perceived impact of spasticity is associated with spatial and temporal parameters of gait in multiple sclerosis.
[HTLV-1-associated myelopathy/tropical spastic paraparesis : A differential diagnosis in multiple sclerosis.]
1st International Symposium on Gait and Balance in MS: Gait and Balance Measures in the Evaluation of People with MS.
IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease.
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.
Magnetic Resonance Imaging in Balo's Concentric Sclerosis. A Case Report.
Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system.
Neuroscience. Myelin--more than insulation.
Pages
« first
‹ previous
…
171
172
173
174
175
176
177
178
179
…
next ›
last »